"
Team:Linkoping Sweden/Project
From 2013.igem.org
| Line 16: | Line 16: | ||
Our ulterior motive behind cloning an antibody in E. coli is that it allows us to engineer the protein after our preferences. What we want to do is connect the VHH antibody to a luciferase protein via a linker. If the translation of the fusion protein is successful, the luciferase will be active when luciferin and ATP is added to the solution.<br /> | Our ulterior motive behind cloning an antibody in E. coli is that it allows us to engineer the protein after our preferences. What we want to do is connect the VHH antibody to a luciferase protein via a linker. If the translation of the fusion protein is successful, the luciferase will be active when luciferin and ATP is added to the solution.<br /> | ||
Another factor to consider is the binding affinity that the antibody part of the fusion protein has for its antigen. This is probably the most critical part of our experiment. The challenge lies in trying to make the antibody regain most of its affinty, while being connected to another protein via a linker. | Another factor to consider is the binding affinity that the antibody part of the fusion protein has for its antigen. This is probably the most critical part of our experiment. The challenge lies in trying to make the antibody regain most of its affinty, while being connected to another protein via a linker. | ||
| - | + | <br /><br /><br /><br /><br /> | |
==Antigen fusion protein== | ==Antigen fusion protein== | ||
[[File:Antigen_rfp.png|thumb|x200px|alt=Example alt text |Fusion protein consisting of a quencher (RFP) linked with a antigen]] | [[File:Antigen_rfp.png|thumb|x200px|alt=Example alt text |Fusion protein consisting of a quencher (RFP) linked with a antigen]] | ||
| Line 23: | Line 23: | ||
The idea behind using RFP is that it absorbs light at the same wavelengths where luciferase emits them, causing a quenching effect through Förster resonance energy transfer (FRET). This FRET will only occur where a fusion antigen has bound to a fusion antibody as fusion antigens and fusion antibodies normally would be to far away for FRET to be observed. <br /> | The idea behind using RFP is that it absorbs light at the same wavelengths where luciferase emits them, causing a quenching effect through Förster resonance energy transfer (FRET). This FRET will only occur where a fusion antigen has bound to a fusion antibody as fusion antigens and fusion antibodies normally would be to far away for FRET to be observed. <br /> | ||
We expect more fusion antigens to be bound to fusion proteins when no free antigen is present in the solution as there will be less competition for the antibodies. This will in turn lead to a difference in emission spectra between a blank containing no free antigens and a sample containing free antigen. Our idea can be summarized as follows. | We expect more fusion antigens to be bound to fusion proteins when no free antigen is present in the solution as there will be less competition for the antibodies. This will in turn lead to a difference in emission spectra between a blank containing no free antigens and a sample containing free antigen. Our idea can be summarized as follows. | ||
| + | <br /><br /><br /><br /><br /> | ||
| + | |||
[[File:Antigen_antibody_rfp_luc.png|center|x700px|alt=Example alt text |Fusion protein consisting of a quencher (RFP) linked with a antigen]] | [[File:Antigen_antibody_rfp_luc.png|center|x700px|alt=Example alt text |Fusion protein consisting of a quencher (RFP) linked with a antigen]] | ||
{{Template:Team Linkoping footer}} | {{Template:Team Linkoping footer}} | ||
Revision as of 17:26, 8 August 2013
The basics
The basics of our project idea is to first grow E.Coli that has been genetically modified to produce an antibody with the enzyme luciferase attached to its constant part. At first the antibody will be constructed to adhere to an egg antigen, but our long time goal is to be able to switch to whichever antigen desired. Luciferase is an enzyme that cleaves luciferin in the presence of ATP, giving rise to a long lasting green light by the principle of luminescence. Luminescence is superior to fluorescence due to, e.g. lack of fading.
Antibody fusion protein
The first step in our project will be to create a fusion protein consisting of a luciferase linked together with a single domain antibody from a camelid, VHH. The idea behind using these antibodies is the fact that they consist only of a single domain. This makes it possible for them to be expressed lesser organisms, such as E. coli, something that would be very hard for conventional antibodies found in other mammals.
Our ulterior motive behind cloning an antibody in E. coli is that it allows us to engineer the protein after our preferences. What we want to do is connect the VHH antibody to a luciferase protein via a linker. If the translation of the fusion protein is successful, the luciferase will be active when luciferin and ATP is added to the solution.
Another factor to consider is the binding affinity that the antibody part of the fusion protein has for its antigen. This is probably the most critical part of our experiment. The challenge lies in trying to make the antibody regain most of its affinty, while being connected to another protein via a linker.
Antigen fusion protein
With the antibody affinity for the antigen maintained, we will have a fusion protein which successfully binds to an antigen and that emits light when luciferin and ATP is added. However, the protein should emit light regardless if it has an antigen bound or not. As such, this alone would not be sufficient to determine the presence of an antigen.
The second stage of our project will be to engineer a similar fusion protein as the first one, but this time it will consist of the antigen linked together with Red Fluorescent Protein (RFP). If successful, our two fusion proteins will have affinity for each other.
The idea behind using RFP is that it absorbs light at the same wavelengths where luciferase emits them, causing a quenching effect through Förster resonance energy transfer (FRET). This FRET will only occur where a fusion antigen has bound to a fusion antibody as fusion antigens and fusion antibodies normally would be to far away for FRET to be observed.
We expect more fusion antigens to be bound to fusion proteins when no free antigen is present in the solution as there will be less competition for the antibodies. This will in turn lead to a difference in emission spectra between a blank containing no free antigens and a sample containing free antigen. Our idea can be summarized as follows.
